Table 1 Baseline Characteristics
HSCT 2–5 yr (n = 26) | HSCT > 5 yr (n = 15) | Chemotherapy (n = 15)c | Healthy (n = 30) | |
|---|---|---|---|---|
Median age, yr (IQR) | 60 (55–63) | 58 (53–62) | 64 (57–69) | 61 (57–66) |
Male sex, n (%) | 15 (58) | 9 (60) | 10 (67) | 10 (33) |
HSCT indication, n (%) | ||||
Leukemia | 11 (42) | 4 (27) | 14 (93) | N/A |
Lymphoma | 2 (8) | 7 (47) | ||
Multiple myeloma | 6 (23) | 1 (6.5) | ||
Myelodysplastic syndrome | 4 (15) | 2 (13) | ||
Othersa | 3 (12) | 1 (6.5) | 1 (7) | |
Type of HSCT, n (%) | ||||
Allogeneic | 20 (77) | 9 (60) | N/A | N/A |
Autologous | 6 (23) | 6 (40) | ||
Time between HSCT or last chemo and the study date, mo (IQR) | 35 (25–44) | 87 (66–91) | 65 (23–104) | N/A |
Previous shingles history, yes, n (%) | 12 (46) | 9 (60) | 6 (40) | 0 (0) |
Shingles within 2 yrs after HSCT or last chemo, n (%) | 9/12 (75) | 6/9 (67) | 5/6 (83) | N/A |
Median years from shingles to the study date (IQR) | 3 (1.5–4)b | 5 (5–7) | 2.5 (1.3–6) | N/A |